Mersana Therapeutics, Inc.
MRSN
$0.3977
-$0.0023-0.58%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 27.77% | 72.39% | 55.31% | 65.63% | 56.50% |
| Total Depreciation and Amortization | -10.51% | -5.85% | 24.38% | 32.60% | 58.51% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -21.19% | 2.17% | -30.06% | -25.08% | -35.75% |
| Change in Net Operating Assets | 47.50% | 83.51% | 85.39% | -186.25% | -26.80% |
| Cash from Operations | 39.77% | 81.39% | 64.66% | -12.59% | 37.61% |
| Capital Expenditure | 100.00% | 100.00% | 100.00% | 85.51% | 50.83% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 143.50% | -72.69% | 209.40% | -3,238.93% | 146.00% |
| Cash from Investing | 148.16% | -72.57% | 201.38% | -5,296.78% | 144.35% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -3,074.24% | 64.62% | 28.79% | 0.00% | -1.54% |
| Issuance of Common Stock | 44.30% | -- | -99.73% | -72.92% | -99.62% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -2,129.35% | 84.25% | -99.79% | -72.95% | -99.78% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 346.39% | -65.47% | -374.05% | -1,539.85% | 78.76% |